On Mar. 27, 1962, the Sabin oral polio vaccine (OPV) type 3 MOPV was licensed in the U.S., as well as the trivalent product. The U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) recommended the restriction of MOPV3 to preschoolers, school-age children, and adults in high-risk groups.

The vaccine was developed in 1961, and was the vaccine of choice in the United States and most other countries until the year 2000. The disease was controlled using the formalin-inactivated Salk polio vaccine (IPV) and the Sabin oral polio vaccine (OPV).

Poliovirus (PV), an enterovirus belonging to the Picornaviridae family is the etiological agent of poliomyelitis, an acute paralytic disease. This disease results from lower motor neuron damage and is characterized by asymmetric persisting weakness (flaccid paralysis).